CL2008000223A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSILOXI-PIRAZOL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS. - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSILOXI-PIRAZOL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS.

Info

Publication number
CL2008000223A1
CL2008000223A1 CL200800223A CL2008000223A CL2008000223A1 CL 2008000223 A1 CL2008000223 A1 CL 2008000223A1 CL 200800223 A CL200800223 A CL 200800223A CL 2008000223 A CL2008000223 A CL 2008000223A CL 2008000223 A1 CL2008000223 A1 CL 2008000223A1
Authority
CL
Chile
Prior art keywords
glucopiranosiloxi
treatment
pharmaceutical composition
neurodegenerative disorders
derivative compound
Prior art date
Application number
CL200800223A
Other languages
Spanish (es)
Inventor
Marion Wienrich
Juergen Reess
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2008000223A1 publication Critical patent/CL2008000223A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200800223A 2007-01-26 2008-01-25 PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSILOXI-PIRAZOL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS. CL2008000223A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101213 2007-01-26

Publications (1)

Publication Number Publication Date
CL2008000223A1 true CL2008000223A1 (en) 2008-05-23

Family

ID=39315016

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800223A CL2008000223A1 (en) 2007-01-26 2008-01-25 PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSILOXI-PIRAZOL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS.

Country Status (4)

Country Link
AR (1) AR065034A1 (en)
CL (1) CL2008000223A1 (en)
TW (1) TW200843785A (en)
WO (1) WO2008090209A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432720A1 (en) * 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
CA2539032A1 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
DE102004058449A1 (en) * 2004-12-03 2006-06-14 Merck Patent Gmbh tetrahydropyran
JP2008007405A (en) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd Carboxamide derivative
US8845999B2 (en) * 2005-05-23 2014-09-30 The Regents Of The University Of California Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
UY29694A1 (en) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO

Also Published As

Publication number Publication date
AR065034A1 (en) 2009-05-13
WO2008090209A3 (en) 2008-10-02
WO2008090209A2 (en) 2008-07-31
TW200843785A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
CL2008000224A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSIL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS.
CL2007002641A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF ALLERGIC DISORDERS, AUTOIMMUNES, INFLAMMATORY DISEASES.
CL2007002234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
CL2007003138A1 (en) COMPOUNDS DERIVED FROM ANILINOPIPERAZINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2007003202A1 (en) COMPOUNDS DERIVED FROM ESPIROINDOLINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS.
CL2007002974A1 (en) COMPOUNDS DERIVED FROM BENZOIMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DGAT1.
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
CL2008000691A1 (en) COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
CL2007003797A1 (en) COMPOUNDS DERIVED FROM PIRROLO PIRIDINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF THE DISEASE OF ALZHEIMER, PARKINSON, CANCER, AMONG OTHER ILLNESSES.
CL2007002479A1 (en) COMPOUNDS DERIVED FROM PIRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
CL2007003244A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2007003352A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROMONOCYCLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CIRCULATORY DISEASES, METABOLIC DISEASES AND / OR DISEASES OF THE CEN NERVOUS SYSTEM
CL2008000531A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES, INHIBITORS OF ASPARTILPROTEASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR, COGNITIVE AND NEURODEGENERATIVE DISEASES SUCH AS THE DISEASE
DK2154971T3 (en) Synergistic pharmaceutical combination for the treatment of cancer
CL2008000223A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLUCOPIRANOSILOXI-PIRAZOL DERIVATIVE COMPOUND; AND USE FOR THE TREATMENT OF ONE OR MORE NEURODEGENERATIVE DISORDERS.
CL2008000754A1 (en) COMPOUND DERIVED FROM NITROGEN HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE TO TREAT CANCER AND HYPERPROLIFERATIVE DISORDERS.
CL2007002916A1 (en) COMPOUNDS DERIVED FROM PIRAZOLILTIENOPIRIDINAS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE INHIBITION OF ESCARAS.
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2012003281A1 (en) Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
CL2007001042A1 (en) COMPOUNDS DERIVED FROM THIOXANTINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE IN THE TREATMENT OF NEUROINFLAMATORY DISORDERS AS MULTIPLE SCLEROSIS, PARKINSON, IN ATEROSCLEROTIC DISORDERS, CARDIO- AND CEREBROVASCULAR, DES
CL2008002162A1 (en) Compounds derived from 3-benzoisoxazole-piperidine; pharmaceutical composition comprising said compounds; and its use for the treatment and / or prevention of cognitive disorders, drug addiction, depression, anxiety, among others.
CL2007001630A1 (en) COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C.
CL2008000794A1 (en) COMPOUNDS DERIVED FROM BIARILO AND HETEROARILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AN IRON DISORDER.
CL2008000440A1 (en) COMPOUNDS DERIVED FROM 4-ARIL-3-PIRIDAZINA, ANTIGONISTS OF THE DOPAMINE 2 RECEPTOR OF RAPIDA DISOCIACION; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE AS ANTIPSYCHOTIC FOR THE TREATMENT OR PREVENTION OF CHICHOPHRENIA,